Follow
Megha Shettigar
Megha Shettigar
Dana-Farber Cancer Institute, Harvard Medical School, BROAD Institute of MIT and Harvard
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
Integrating oncolytic viruses in combination cancer immunotherapy
PK Bommareddy, M Shettigar, HL Kaufman
Nature Reviews Immunology 18 (8), 498-513, 2018
5572018
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
C Gstalder, D Liu, D Miao, B Lutterbach, AL DeVine, C Lin, M Shettigar, ...
Cancer discovery 10 (9), 1296-1311, 2020
562020
Deletion of mouse Setd4 promotes the recovery of hematopoietic failure
X Feng, H Lu, J Yue, M Shettigar, J Liu, LK Denzin, Z Shen
International Journal of Radiation Oncology* Biology* Physics 107 (4), 779-792, 2020
62020
Abstract A48: Inactivation of Fbxw7 impairs dsRNA sensing and confers resistance to PD-1 blockade
C Gstalder, D Liu, D Miao, A Devine, B Lutterbach, P Pancholi, ...
Cancer Immunology Research 8 (3_Supplement), A48-A48, 2020
2020
Ubiquitylation of the Paf oncoprotein and interaction with PCNA is essential for hematopoietic stem cell function and development.
M Shettigar, M Savic, DB Sant’Angelo, LK Denzin
The Journal of Immunology 196 (1_Supplement), 52.2-52.2, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–5